Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation

Ibrahim El-Serafi1, Manuchehr Abedi-Valugerdi1, Zuzana Potácová1,2, Parvaneh Afsharian1,3, Jonas Mattsson4,5, Ali Moshfegh6, Moustapha Hassan1,2*

1 Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden, 2 Clinical Research Centre (Novum), Karolinska University Hospital-Huddinge, Stockholm, Sweden, 3 Department of Genetics, Royan Institute, Tehran, Iran, 4 Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital-Huddinge, Stockholm, Sweden, 5 Department of Therapeutic Immunology, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden, 6 Cancer Centre of Karolinska (CCK), Department of Oncology-Pathology, Karolinska Institutet, Solna, Stockholm, Sweden

Abstract

Background: Hematopoietic stem cell transplantation is a curative treatment for several haematological malignancies. However, treatment related morbidity and mortality still is a limiting factor. Cyclophosphamide is widely used in conditioning regimens either in combination with other chemotherapy or with total body irradiation.

Methods: We present the gene expression profile during cyclophosphamide treatment in 11 patients conditioned with cyclophosphamide for 2 days followed by total body irradiation prior to hematopoietic stem cell transplantation. 299 genes were identified as specific for cyclophosphamide treatment and were arranged into 4 clusters highly down-regulated genes, highly up-regulated genes, early up-regulated but later normalized genes and moderately up-regulated genes.

Results: Cyclophosphamide treatment down-regulated expression of several genes mapped to immune/autoimmune activation and graft rejection including CD3, CD28, CTLA4, MHC II, PRF1, GZMB and IL-2R, and up-regulated immune-related receptor genes, e.g. IL1R2, IL18R1, and FLT3. Moreover, a high and significant expression of ANGPTL1 and c-JUN genes was observed independent of cyclophosphamide treatment.

Conclusion: This is the first investigation to provide significant information about alterations in gene expression following cyclophosphamide treatment that may increase our understanding of the cyclophosphamide mechanism of action and hence, in part, avoid its toxicity. Furthermore, ANGPTL1 remained highly expressed throughout the treatment and, in contrast to several other alkylating agents, cyclophosphamide did not influence c-JUN expression.

Introduction

Hematopoietic stem cell transplantation (HSCT) is currently used as a curative treatment for a wide range of diseases, including malignancies such as leukaemia and lymphomas and non-malignant diseases such as metabolic and haematological disorders. Conditioning regimens - either a combination of cytostatics or cytokostatics together with radiotherapy - are designed to prepare the patient to receive donor stem cells. Cytostatics are administered in order to eliminate malignant cells, provide free space for the donor cells and suppress the immune system in order to prevent graft rejection [1].

Cyclophosphamide (Cy) is an alkylating agent widely used as a part of the conditioning regimen prior to HSCT and for the treatment of haematological malignancies and solid tumours. Cy is used either in combination with other cytostatics or with total body irradiation (TBI) [2]. It acts on DNA by attaching an alkyl group to the guanine base of DNA at the number 7 nitrogen atom of the imidazole ring and leads to guanine-adenine intra-strand cross-linking. This damage to the DNA strand can trigger apoptosis when the cellular machinery fails to repair it.

Cy is also a potent immunosuppressive agent i.e. it is capable of attenuating both humoral and cell-mediated immune responses [3]. Due to these immunosuppressive effects, Cy is used in the treatment of several autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus [4].

Cy is a prodrug that is metabolized by cytochrome P450 to its main active metabolite, 4-hydroxycyclophosphamide (4-OH-Cy), which comprises about 90% of the total Cy dose [5]. 4-OH-Cy is subsequently converted to phosphoramide mustard and acrolein, which is nephrotoxic. An alternative pathway of Cy
transformation is N-dechloroethylation. Moreover, Cy is partly metabolized to the inactive metabolite 2-dechloroethyl-Cy and to chloroacetaldehyde, which is neurotoxic [6–9].

Studies on Cy kinetics have shown a high inter-individual variation in elimination half-life and clearance [6,9]. This variation may be explained by polymorphisms in CYP2B6, the main enzyme responsible for the conversion of Cy to its active form [10–12].

Several studies have investigated the clinical efficacy of Cy alone or in combination with other cytostatics or radiotherapy [2,13]. However, the contribution of Cy to the outcome of HSCT and, more importantly, the mechanisms by which Cy exerts its effect on immune cells has not yet been addressed.

In the past decade, the advent of DNA microarray technology together with the availability of the complete nucleotide sequence of the human genome have allowed elucidation of the molecular mechanisms in several diseases [14,15] or treatment regimens [16,17]. In order to understand the effect of high dose cyclophosphamide on different genes, we employed the DNA microarray to investigate the gene expression profile in peripheral mononuclear cells of patients suffering from haematological malignancies and undergoing conditioning regimen consisting of Cy followed by TBI. We followed the gene profile pre-, during and after treatment.

Materials and Methods

Patients and Treatment

Eleven patients were enrolled in this study. The patients were admitted at the Centre for Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital-Huddinge. The study was approved by the ethical committee of Karolinska Institutet (616/05) and written informed consent was obtained from the patients or, in case of paediatric patients, their parents. Twelve samples from healthy donors, who had given their written consent, were run concomitantly as negative controls. The ethics committee approved the consent procedure. Six of these patients were diagnosed with acute lymphocytic leukaemia (ALL), two with acute myeloid leukaemia (AML), two with T-cell lymphoma and one with chronic lymphocytic leukaemia (CLL). Patient characteristics are presented in Table 1.

All patients received an i.v. infusion of Cy 60 mg/kg/day once daily for two days followed by fractionated TBI 3 Gy (gray) × 4, except the first patient who only received 6 Gy in total. Blood samples were collected from each patient before the start of Cy infusion, 6 h after the first dose of Cy, before and 6 h after the second dose of Cy. Samples have been numbered with the patient’s number followed by −1, −2, −3 and −4.

All patients with unrelated donors received antithymocyte globulin (ATG, Thymoglobulin, Genzyme, Cambridge, MA, USA), at a total dose of 6 mg/kg given at day −4,−1 during the conditioning treatment. The single exception was the first patient, who had a sibling donor and received Alemtuzumab 30 mg × 1 due to CD52 expression of the leukaemia.

GVHD Prophylaxis

GVHD prophylaxis consisted of cyclosporine (CsA) in combination with four doses of methotrexate (MTX) [19]. During the first month, blood CsA levels were kept at 100 ng/mL when a sibling donor was used, and at 200–300 ng/mL when an unrelated donor was used. In the absence of GVHD, CsA was discontinued after three to four months for patients with sibling donors and six months for patients with MUD.

Diagnosis and Treatment of GVHD

Acute and chronic GVHD were diagnosed on the basis of clinical symptoms and/or biopsies (skin, liver, gastrointestinal tract, or oral mucosa) according to standard criteria [19]. The patients were treated for grade I acute GVHD with prednisolone, starting at a dosage of 2 mg/kg/day, which was successively lowered after the initial response. Chronic GVHD was initially treated with CsA and steroids. In most cases, daily prednisone at 1 mg/kg per day and daily CsA at 10 mg/kg per day were used [20].

Blood Sampling and RNA Extraction

Blood samples for RNA extraction were collected in PAXgene tubes (BD, Stockholm, Sweden). RNA was extracted using QuickPrep Total RNA Extraction Kit (GE Life Sciences, Uppsala, Sweden) according to the manufacturer’s instructions and then quantified by measuring the absorbance at 260 and 280 nm. All samples were stored at −80°C.

Gene Expression Assay and Analysis

Purified mRNA was subjected to analysis of global gene expression by using NimbleGen microarrays (Roche Diagnostics Scandinavia, Bromma, Sweden). Data were analyzed using GeneSpring GX (Agilent, CA, USA). The expression data were normalized using quantile normalization and the gene expression data were generated using the Robust Multichip Average algorithm. Significant differences in gene expression were determined by ANOVA. The selection threshold of a false discovery rate (FDR) was <5% and the fold change in the SAM output result was >2. The complete data (ID no. 20051907) is available via the GEO database with the accession number “GSE51907”.

Pathway identification and reporting was performed using IPA software (Ingenuity, Qiagen, CA, USA) and Kyoto Encyclopaedia of Genes and Genomes software (KEGG) (Kyoto University Bioinformatics Centre, Japan).

cDNA Synthesis and Real Time PCR (qRTPCR)

Two micrograms of RNA were reversed transcribed to complementary DNA (cDNA) using the TaqMan Reverse Transcriptase cDNA Kit (Applied Biosystems, Roche, NJ, USA) and then stored at −80°C. TaqMan gene expression assay (Applied Biosystems, Stockholm, Sweden) was performed by means of the FAM dye labelling system according to the manufacturer’s instructions. The assay was performed for the selected genes that showed significantly high expression, ANGPTL1 and c-JUN (assay IDs; Hs00559786_m1 and Hs01103582_s1, respectively) and GAPDH (assay ID; Hs00275899_1g) as a housekeeping gene (Applied Biosystems, Stockholm, Sweden). Real time PCR (qRTPCR) reactions were performed in a 384-well plate thermal cycler ABI 7900 (Applied Biosystems, Stockholm, Sweden) in a total volume of 10 µL and results were normalized against the housekeeping gene GAPDH. Twelve samples from healthy donors were run concomitantly as negative controls.

Results

Outcome of HSCT after Conditioning with Cy and TBI

As shown in Table 1, all patients received allogeneic HSCT either from their siblings (5 patients) or from MHC-matched unrelated donors (MUD) (5 patients) after conditioning with Cy and TBI. Stem cells from peripheral blood (PBSC) were given to 7 patients, and 3 patients received bone marrow (BM). One patient received a double umbilical cord blood (DUCB) transfusion.
## Table 1. Patient characteristics.

| Patient Code | Age (years) | Diagnosis                  | Conditioning regimen | Stem cells source | Donor | CD 34 dose/Kg | Disease status at HSCT | Acute GVHD | Outcome | Cause of death |
|--------------|-------------|----------------------------|----------------------|-------------------|-------|---------------|------------------------|------------|---------|----------------|
| P 1          | 57          | B-CLL                      | CP+TBI (6 Gy)+ Alemtuzumab | PBSC              | Sib   | 14.7×10^6     | Transformed            | Grade II  | † 10 months | Relapse         |
| P 2          | 38          | T cell lymphoma            | CP+TBI               | BM                | Sib   | 2.9×10^6      | PR                     | Grade II  | † 19 months | Relapse         |
| P 3          | 31          | AML                        | CP+TBI+ATG           | BM                | MUD   | 2×10^9        | CR2                    | Grade II  | † 6 months  | Pneumonia       |
| P 4          | 10          | T-ALL                      | CP+TBI+ATG           | BM                | Sib   | 6.48×10^8     | CR1                    | Grade I   | † 12 months | Relapse         |
| P 5          | 26          | Pre B-ALL                  | CP+TBI+ATG           | PBSC              | MUD   | 1.35×10^6     | CR2                    | Grade II  | † 35 months | Relapse         |
| P 6          | 19          | ALL                        | CP+TBI+ATG           | PBSC              | MUD   | 1.35×10^6     | CR3                    | No         | † 9 months  | Relapse & pneumonia |
| P 7          | 51          | AML                        | CP+TBI+ATG           | PBSC              | Sib   | 10.6×10^5     | Refractory             | Grade I   | Alive 7.5 years | –               |
| P 8          | 25          | Pre B-ALL                  | CP+TBI+ATG           | PBSC              | Sib   | 7.3×10^6      | CR2                    | Grade II  | Alive 7.5 years | –               |
| P 9          | 14          | T-ALL                      | CP+TBI+ATG           | PBSC              | MUD   | 1.99×10^6     | CR2                    | Grade II  | Alive 7.2 years | –               |
| P 10         | 41          | T cell lymphoma            | CP+TBI+ATG           | PBSC              | MUD   | 9.3×10^6      | Relapse                | Grade I   | † 51 days  | Invasive fungal infection |
| P 11         | 26          | T-ALL                      | CP+TBI+ATG           | DUCB              | DUCB  | 0.5×10^5      | CR2                    | Grade I   | † 11 months | Relapse         |

**Abbreviations:** GVHD, graft versus host disease; P, patient; CLL, chronic lymphoblastic leukaemia; AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; CP, cyclophosphamide; fTBI, fractionated total body irradiation; ATG, antithymocyte globulin; PBSC, peripheral blood stem cells; BM, bone marrow; Sib, HLA-identical sibling; MUD, matched unrelated donor; DUCB, Double umbilical cord blood; CR, complete remission; PR, partial remission; † survival.

doi:10.1371/journal.pone.0086619.t001
Most of the patients were in remission at the time of transplantation (8/11, 72.7%). Acute GVHD, either grade I or grade II, was reported in 10 patients (90.9%). The overall survival was 27.3% (3/11 patients) and relapse was the main cause of death in most of the patients (6/8, 75%).

Identification of Differentially Expressed Genes and Gene Clusters Related to Cy Treatment

We assessed the overall patterns of gene expression in 11 patients with haematological malignancies treated with Cy. The assessment was performed utilizing a hierarchical clustering

**Figure 1. Heat map of patient gene expression during Cy treatment.** Genes expression for genes specific for Cy before and though the treatment (A). Differential expression of a group of 299 genes was identified as being specific for Cy treatment. After subjecting these genes to hierarchical clustering analysis, 4 clusters of up- and down-regulated genes were identified as: highly down-regulated genes (cluster 1), highly up-regulated genes (cluster 2), early up-regulated but later normalized genes (cluster 3) and moderately up-regulated genes (cluster 4) as seen in B. doi:10.1371/journal.pone.0086619.g001
analysis of the signal ratios of all arrays. The heat map representing array clustering based on normalized probe intensity showed a high inter-individual variation, as expected (Figure 1A).

In the present study we observed variation in several thousands of genes during and after Cy treatment. However, after fold-change filtering (at least 2-fold compared to time 0, i.e. before treatment), differential expression of a group of 299 genes was identified as being specific for Cy treatment. By subjecting these genes to hierarchical clustering analysis, we were able to identify 4 clusters of up- and down-regulated genes which matched the chronological cascade of gene expression by cyclophosphamide treatment: highly down-regulated genes (cluster 1), highly up-regulated genes (cluster 2), early up-regulated but later normalized genes (cluster 3) and moderately up-regulated genes (cluster 4) (Figure 1B).

**Highly down-regulated genes (cluster 1).** The first cluster represents genes that were relatively up-regulated in all patients prior to cyclophosphamide treatment; however, this cluster was down-regulated at 6 h post administration followed by a pronounced decrease in expression at 30 h (i.e. 6 h after the second dose; Fig. 2A). This cluster possessed the highest number of genes (139 genes, Table 2). The majority of these genes belonged to the immune system and its functions (Table 3). Moreover, further analysis of biological pathways related to these genes showed that a majority of immune- (e.g. T cell receptor signalling, natural killer cell mediated cytotoxicity and graft rejection), autoimmune- (e.g. autoimmune thyroid disease pathway, type 1 diabetes mellitus and rheumatoid arthritis) and inflammation-related processes were down-regulated by the Cy treatment (Figure 3A).

**Highly up-regulated genes (cluster 2).** In contrast to cluster 1, this group of genes exhibited a constant and high up-regulation in response to Cy treatment (Fig. 2B). In this cluster, 41 up-regulated genes were identified (Table 2). The majority of these genes are involved in 3 important biological pathways involving cytokine-cytokine receptor interaction, transcriptional misregulation in cancer and hematopoietic cell lineage (Table 3 and Fig. 3B). Only one gene in this cluster was found to be related to the acute myeloid leukaemia pathway (Table 3 and Fig. 3B).

**Early up-regulated but later normalized genes (cluster 3).** This group of genes exhibited significant up-regulation at an early time point in Cy treatment, but the expression was later normalized to the same level as before the start of treatment (Fig. 2C). This cluster included 33 genes (Table 2). Analysis of biological pathways related to these genes showed that although several pathways are involved (Table 3), only one gene in each pathway is affected by treatment with Cy (Fig. 3C).

**Moderately up-regulated genes (cluster 4).** Finally, treatment with Cy resulted in moderate up-regulation of a group of genes, mainly by the end of treatment (6 hr after the second dose; Fig. 2D). There were 90 genes in this cluster (Table 2) and the biological pathway analysis demonstrated that several pathways including cytokine-cytokine receptor interaction (4 genes), Jak-STAT signalling pathway (2 genes) and TGF-beta signalling pathway (2 genes) are related to this cluster (Table 3 and Fig. 3D).
Disease-related Common Up-regulated Genes

Hierarchical clustering analysis showed that 2 genes, angiotensin-like-1 (ANGPTL1) and c-JUN proto-oncogene (c-JUN), were considerably up-regulated prior to, during and after treatment with Cy in all tested patients. Further, these results were confirmed by qRTPCR and showed that these two genes were up-regulated in the patients treated with Cy. Figure 4A shows the results obtained from qRTPCR analysis of ANGPTL1, the gene expression was up-regulated from time 0 e.g. before Cy treatment and continued to be at a high expression level on 6 h after the first dose, 24 h (time before second dose) and at 6 h after treatment with Cy in all tested patients. Further, these results were confirmed by qRTPCR and showed that these two genes were up-regulated in the patients treated with Cy.

Discussion

This is the first global gene expression profiling study of patients suffering from haematological malignancies, treated with Cy as a conditioning regimen and undergoing HSCT. The data analysis has generated comprehensive knowledge that can be employed in understanding the rationales by which Cy is used as an immunosuppressive/immunoregulatory or conditioning agent. Our first set of findings that treatment with Cy down-regulated the expression of several genes mapped to immune/autoimmune activation, allograft rejection and GVHD strongly confirm that this alkylation agent is a potent immunosuppressive agent. In this connection, the most noticeable down-regulated genes are CD3, CD28, CTLA4, MHC II, PRF1, GZMB and IL-2R.

CD3 molecule is a complex protein that is expressed as a co-receptor in all mature T lymphocytes and is a subset of NK cells [21]. This co-receptor molecule plays a key role in T cell activation and is therefore a potential target for several drugs, including monoclonal antibodies for the treatment of different autoimmune diseases [22,23]. In this respect, down-regulation of CD3 gene expression implies that the initial event of T cell activation, which requires the formation of a complex consisting of CD3 and T cell receptor, is impaired upon treatment with Cy.

CD28 and CTLA4 are two surface molecules that play a crucial role in activation and subsequent regulation of cell-mediated immune responses [24]. CD28 is constitutively expressed on the surface of T cells and provides a key co-stimulatory signal upon interaction with CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells [25]. In contrast, CTLA4 is transiently expressed in activated T cells. CTLA4, by binding to CD80 or CD86, delivers negative signals, which leads to T cell inactivation [25]. Our observation that treatment with Cy down-regulated the expression of both CD28 and CTLA4 suggests that this drug exerts dual effects on T cells as it suppresses the early phase of T cell activation as well as prolongs the activity of effector T cells.

MHC II molecules (major histocompatibility complex class II molecules) are the key molecules involved in presenting antigens to CD4+ T cells. These molecules are constitutively expressed in professional (macrophages, dendritic and B cells) and non-professional (thymic epithelial cells) antigen presenting cells [26]. By binding to foreign peptides, these molecules provide “signal 1”
for activation of CD4+ T cells. Thus, down-regulation of the expression of MHC II in Cy treated patients implies that this drug prevents T cell activation by impairing the process of MHC II mediated antigen presentation. Furthermore, this mechanism of action can also explain the efficacy of Cy in the treatment of autoimmune diseases (e.g. RA and SLE) where antigen presentation and antigen presenting cells (in particular B-cells) play a crucial role.

Due to its effect on autoimmune diseases, cyclophosphamide has recently been used in high doses after HSCT to prevent graft rejection and GVHD [27]. Moreover, HLA matching does not seem to be important if the patient receives post-transplantation Cy, which is a great advantage to patients lacking conventional donors [28,29].

The PRF1 (perforin-1) gene encodes a cytolytic protein, which is found in cytotoxic T cells and NK cells. PRF1 shares similarities in both structure and function with complement component 9 (C9) [30]. Like BRF1, GZMB (granzyme B) is a protease expressed by cytotoxic T lymphocytes and NK cells and induces apoptosis on target cells [31]. It has been demonstrated that granzyme can

| Cluster | Pathways                                      | Genes                                      |
|---------|----------------------------------------------|--------------------------------------------|
| Cluster 1 | T cell receptor signalling                     | CTLA4, CD3\textsubscript{c}, CD3\textsubscript{d}, CD28, Lck, LAT, RasGRF1, NFAT |
|         | Natural killer cell mediated cytotoxicity       | Lck, LAT, NFAT, 284, GZMB, PRF1             |
|         | HTLV-1 infection                               | CD3, IL2R, NFAT, Ras, Lck                  |
|         | Cytokine-cytokine receptor interaction          | CX3CR1, CCR4, IL5RA, IL2RB, CSF1R           |
|         | Type 1 diabetes mellitus                       | INS, MHC-II, CD28, PRF1, GZMB              |
|         | Autoimmune thyroid disease                     | CTLA4, CD28, PRF1, GZMB                    |
|         | Hematopoietic cell lineage                     | CD3, CD115, IL5RA, CD49                    |
|         | Cell adhesion molecules                        | CD28, CTLA4, 5Pn, ITGAA4                   |
|         | Measles                                        | CD3, CD28, IL2R                            |
|         | Allograft rejection                             | CD28, PRF1, GZMB                           |
|         | PI3K-Akt signalling                             | RTK, Cytokine R, ITG A                     |
|         | Transcriptional misregulation in cancer         | LMO2, PAX3, PAX7                           |
|         | Graft-versus-host disease                      | CD28, PRF1, GZMB                           |
|         | RNA transport                                  | Exp5, Nup37, Nup205                         |
|         | FC epsilon R signalling                        | Fc\textsubscript{e}R\alpha, LAT             |
|         | Pathways in cancer                             | Ra1GDS, MCSFR                               |
|         | DNA replication                                | Mcm4, Mcm7                                 |
|         | Cell cycle                                     | Mcm4, Mcm7                                 |
|         | MAPK signalling                                | RasGRF1, Ras                               |
|         | Rheumatoid arthritis                           | CD28, CTLA4                                |
|         | NF- Kappa B signalling                         | Lck, LAT                                   |
| Cluster 2 | Cytokine-cytokine receptor interaction         | FLT3, IL1R2, IL1R1                         |
|         | Hematopoietic cell lineage                     | CD135, CD121                               |
|         | Acute myeloid leukemia                         | AML1                                       |
| Cluster 3 | MAPK signalling                               | TrkA/B                                     |
|         | Steroid hormone biosynthesis                   | 17\beta-estradiol                           |
|         | Gastric acid secretion                         | KCN                                        |
|         | Alcoholism                                     | TrkB                                       |
|         | Leukocyte transendothelial migration           | Thyl                                       |
|         | Neuroactive ligand-receptor interaction        | ADR                                        |
|         | Neurotrophin signalling                        | TrkB                                       |
|         | Jak-STAT signalling                            | Sprouty                                    |
|         | Ovarian steroidogenesis                        | 17\beta-HSD                                 |
|         | MAPK signalling                                | TrkA/B                                     |
| Cluster 4 | Cytokine-cytokine receptor interaction         | IL13RA1, XEDAR, ACVR1B, BMPR2              |
|         | Jak-STAT signalling                            | CytokineR, SOCS                            |
|         | TGF-beta signalling                            | BMPR1, ActivinR1                           |
|         | Fc gamma R-mediated phagocytosis               | Myosin X                                   |
|         | Complement and coagulation cascade             | coagulation factor VIII                     |

doi:10.1371/journal.pone.0086619.t003
access its target cells through pores formed by perforin [32]. Our observation that the expression of BRF1 and GZMB genes are down-regulated upon treatment with Cy strongly suggests that cytotoxic activity of the immune cells mainly mediated by CD8+ T and NK cells is also lessened by Cy.

IL-2R (Interleukin-2 receptor) is expressed on the activated T cells as well as regulatory T (T_{reg}) cells (also known as suppressor T

Figure 3. The pathways related to each cluster and number of genes involved in each cluster. Cluster 1 for highly down-regulated genes throughout the treatment (A) included the highest number of genes. The majority of these genes belonged to the immune system and its functions. Cluster 2 for highly up-regulated genes throughout the treatment (B), the majority of these genes are involved in 3 important biological pathways involving cytokine-cytokine receptor interaction, transcriptional misregulation in cancer and hematopoietic cell lineage. Cluster 3 showed early up-regulated but later normalized genes (C), these genes were more related to biological pathways including Jak-STAT and MAPK signalling. Cluster 4 showed moderately up-regulated genes (D), the pathway analysis demonstrated that several pathways including cytokine-cytokine receptor interaction, Jak-STAT signalling pathway and TGF-beta signalling are involved.

doi:10.1371/journal.pone.0086619.g003
cells). Upon binding to IL-2, IL-2R promotes cell cycle progression through phase G1 of the cell cycle, which leads to the onset of DNA synthesis and replication [33]. Therefore, down-regulation of IL-2R gene expression in Cy treated patients may prevent alloreactivity against donor hematopoietic stem cells. Furthermore, this reduction in IL-2R expression might also attenuate the number of Treg cells, which are known to play an unfavourable role in malignancies [34,35]. In line with this statement, it has been shown that Cy can suppress Treg cells and allow more effective induction of antitumor immune responses [36].

In addition to the genes related to the immune system, our findings also demonstrated that treatment with Cy down-regulates the expression of several genes (e.g., Ras, LMO2, MCM4 and MCM7) that are related to cancer development and cell cycle progression. For instance, Ras (rat sarcoma) oncoproteins are known to be responsible for signal transmission inside the cells and for participating in cell growth, differentiation and survival [37]. Oncogenic mutations in Ras genes have been detected in several human cancers [38,39].

The LMO2 (LIM domain only 2) gene encodes a cysteine-rich, two protein structural domain that plays an important role in hematopoietic development; moreover, its ectopic expression in T cells leads to the onset of acute lymphoblastic leukaemia (ALL) [40]. In mice, LMO2 induced precancerous stem cells and even initiated leukaemia (T-ALL) by inducing thymocyte self-renewal [41,42].

Finally, minichromosome maintenance proteins (MCM) 4 and 7 are known to be essential for the initiation of genomic replication [43] and their down-regulation during Cy treatment confirms the ability of this drug to reduce cancer size by slowing cell replication. MCM4 and MCM7 were found in both DNA replication and cell cycle pathways. Thus, Cy induced down regulation in Ras, LMO2, MCM4 and MCM7 genes might shed light on the mechanisms underlying the anti-cancer effects of Cy.

Our findings in this study have also demonstrated that in addition to the down-regulated genes, several genes are up-regulated during treatment with Cy. Most of these genes are immune-related receptor genes, e.g. IL1R2 (interleukin 1 receptor, type II or CD121b), IL18R1 (interleukin-18 receptor 1 or CDw218a) and FLT3 (Fms-like tyrosine kinase 3, or CD135). IL1R2 is a protein expressed on B cells, monocytes and neutrophils and functions as a molecular decoy that sequesters IL-1β and blocks the initiation of downstream signalling, thereby preventing inflammation [44]. Moschella et al. have reported that IL-1β was increased to reach maximum concentration at day 3 after Cy administration which is in good agreement with our finding [45]. On the other hand, IL18R1 is a cytokine receptor that specifically binds interleukin 18 (IL18) and is essential for IL18 mediated signal transduction. IFN-α as well as IL12 are reported to induce the expression of this receptor in NK and T cells. Interestingly, IL18R1 and IL1R2 genes along with three other members of the interleukin 1 receptor family, including IL1R1, IL1R2 (IL-1Rrp2), and IL1RL1 (T1/ST2) form a gene cluster on chromosome 2q [46]. Thus, Cy induced increase in expression of IL1R2 and IL18R1 suggests that cytokine receptor genes located on chromosome 2q are susceptible to Cy. In a recent publication, Moscella et al. have reported that Cy has activated IFN-α signature and IFN-α –induced proinflammatory mediators. Moreover, Cy also has induced expansion and activation of IL1R1 and other receptors [47]. These results confirm our finding; however, further studies are required to confirm mechanisms underlying this hypothesis.

FLT3 is a protein expressed on the surface of many hematopoietic progenitor cells and plays an important role in the development of B and T progenitor cells [48]. However, it remains to be elucidated if increased expression of FLT3 implies that treatment with Cy might lead either directly or indirectly to mobilization of hematopoietic progenitor cells to the periphery.

Our results showed a significant increase (confirmed by qRT-PCR) in the expression of angioptin-related protein 1 (ANGPTL1) and c-JUN proto-oncogene (c-JUN) genes in all patients. The high expression was independent of Cy treatment. These two genes are known to play an important role in cancer, i.e. ANGPTL1, which is a member of the vascular endothelial growth factor family, was reported to mediate a defence mechanism against cancer growth and metastasis. In this respect, Kuo et al. reported the inverse correlation between the expression of ANGPTL1 and cancer invasion and lymph node metastasis in lung cancer patients and experimental cancer models [49].

Overexpression of c-JUN has been shown in several human cancer types such as non-small cell lung cancer, breast cancer, colon cancer and lymphomas [50–53]. Moreover, c-JUN was reported to be associated with proliferation and angiogenesis in invasive breast cancer [34]. Jiao et al. have reported that c-JUN induced epithelial cellular invasion in breast cancer [55]. Cancer cells are rapidly dividing and c-JUN is important for progression through the G1 phase of the cell cycle [36]. c-JUN antagonizes P53 expression which is a cell cycle arrest inducer [57]. Moreover,
c-JUN is an apoptosis down-regulator, which is important for cancer cell survival [56]. c-JUN was reported to promote BCR-ABL induced lymphoid leukemia [58]. Furthermore, the expression of c-JUN was reported to be enhanced in chemotherapy resistant tumors [59-61]. In the present investigation, the high expression of ANGPT1 and c-JUN genes was observed throughout the treatment with no effect of Cy therapy on these genes. Thus, based on our findings and the reported studies, we propose that these genes might be considered as potential markers for therapeutic efficacy connected to haematological malignancies. In addition, we strongly believe that targeting the gene expression of c-JUN might have therapeutic potential for these diseases [62,63].

In conclusion, our results in the present study provide significant information about the alterations in gene expression caused by Cy treatment. We demonstrate here that Cy induces both down- and up-regulation in genes, mainly belonging to the immune system.

This knowledge can be expanded further to evaluate which Cy metabolites are responsible for these effects and how Cy can be employed to target specific immune function in order to optimize Cy treatment and/or to minimize the treatment related toxicity and hence enhance HSCT clinical outcome. Our findings also show Cy independent over expression of some genes that have been reported in solid tumours. These may suggest that these genes may be used as a target treatment for haematological malignancies. However, several studies are warranted.

Author Contributions
Conceived and designed the experiments: MH ZP PA. Performed the experiments: ZP PA MH AM IELS. Analyzed the data: AM MAV IELS MH JM ZP. Contributed reagents/materials/analysis tools: AM MAV IELS MH JM ZP. Wrote the paper: AM MAV IELS MH JM ZP PA.

References
1. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, et al. (2008) Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA: the journal of the American Medical Association 299: 925–936.
2. Reynolds M, McCann SR (1989) A comparison between regimens containing chemotherapy alone (busulfan and cyclophosphamide) and chemotherapy (V. RAPID) plus total body irradiation on marrow engraftment following allogeneic bone marrow transplantation. Eur J Haematol 43: 314–320.
3. Daleboudt GM, Reinders ME, den Hartigh J, Huizinga TW, Rabelink AJ, et al. (2013) Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Clin J Am Soc Nephrol 22: 171–179.
4. Binotto G, Trentin I, Semenzato G (2003) TGF-β and cyclophosphamide: effects on immunosurveillance. Oncology 63: 17–20.
5. Sladek NE (1980) Metabolism of oxazaphosphorines. Pharmacology & therapeutics 17: 391–395.
6. Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, et al. (2004) Haplotype structure of the CALM1 gene in healthy Koreans. Ann Hum Genet 68: 15–20.
7. Chang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of CYP2B6 in a Korean population. Drug Metabolism and Disposition 32: 1541–1547.
8. Chiang TK, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53: 5629–5637.
9. Ren S, Yang JS, Kalkhorn TF, Slattert JYT (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57: 4229–4235.
10. Xie H, Griskevicius L, Stahlé L, Hassan Z, Yasar U, et al. (2006) Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharmacol 547: 35–41.
11. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, et al. (2005) Influence of Cy therapy on these genes. Thus, based on our findings and the reported studies, we propose that these genes might be considered as potential markers for therapeutic efficacy connected to haematological malignancies.
38. Goodsell DS (1999) The molecular perspective: the ras oncogene. Stem Cells 17: 235–236.
39. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Research 49: 4682–4689.
40. El Omari K, Housdally SJ, Tuluhalar K, Karia D, Vyas P, et al. (2011) Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood 117: 2146–2156.
41. McCormack MP, Curtis DJ (2010) The thymus under siege: Lmo2 induces precancerous stem cells in a mouse model of T-ALL. Cell Cycle 9: 2267–2268.
42. McCormack MP, Young LF, Vasudevan S, de Graaf CA, Codrington R, et al. (2010) The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science (New York, N Y ) 327: 879–883.
43. Kearney SE, Labib K (1998) MCM proteins: evolution, properties, and role in DNA replication. Biochimica et biophysica acta 1398: 113–136.
44. Mantovani A, Bonecchi R, Martinez FO, Galliera E, Perrier P, et al. (2003) Tuning of innate immunity and polarized responses by decoy receptors. Int Arch Allergy Immunol 132: 109–115.
45. Moschella F, Valentini M, Arico E, Macchia I, Sestili P, et al. (2011) Unraveling cancer chemoinmunomunotherapeutic mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res 71: 3520–3539.
46. Dale M, Nicklin MJ (1999) Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1R1L2 (IL-1Rrp2), IL1R1L1 (T1/ST2), and IL1R1R1 (IL-1Rrp) on human chromosome 2q. Genomics 37: 177–179.
47. Moschella F, Torelli GF, Valentini M, Urbani F, Buccone C, et al. (2013) Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients’ blood cells: implications for cancer chemoinmunotherapy. Clin Cancer Res 19: 4249–4261.
48. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, et al. (1993) Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 82: 1110–1119.
49. Kuo TC, Tan CT, Chang YW, Hong CC, Lee WJ, et al. (2013) Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. The Journal of clinical investigation 123: 1082–1095.
50. Szabo E, Riffle ME, Steinberg SM, Birrer MJ, Linnoila RI (1996) Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Research 56: 305–315.
51. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, et al. (1999) cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063–6070.
52. Zhang Y, Pu X, Shi M, Chen L, Song Y, et al. (2007) Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model. BMC Cancer 7: 145.
53. Zhang HS, Yan B, Li XB, Fan L, Zhang YF, et al. (2012) PAN2 protein induces expression of cyclin D1 through activating AP-1 protein and promotes proliferation of colon cancer cells. Journal of Biological Chemistry 287: 44164–44172.
54. Vleugel MM, Greijer AE, Bos R, van der Wall E, van Dierg PJ (2006) c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol 37: 668–674.
55. Xiao J, Katiyar S, Willnarth NE, Liu M, Ma X, et al. (2010) c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 285: 4218–4226.
56. Wisdom R, Johnson RS, Moore C (1999) c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. The EMBO journal 18: 188–197.
57. Schreiber M, Kollbus A, Piu F, Szabooski A, Mohle-Steinlein U, et al. (1999) Control of cell cycle progression by c-Jun is p53 dependent. Genes & development 13: 667–670.
58. Kollmann K, Keller G, Ott RG, Schreiber R, Zebedin-Brandl E, et al. (2011) c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methyl-ation of the 5’ region of CrkII. Blood 117: 4063–4075.
59. Ritchie MK, Bergolz VV, Allan WP, Yalowich JC (1994) Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol 48: 525–533.
60. Rubin E, Kharbanda S, Gunji H, Weichselbaum R, Kufe D (1992) cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res 52: 878–882.
61. Zhou J, Gupta K, Yao J, Ye K, Panda D, et al. (2002) Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 277: 39777–39785.
62. Gurzoz EN, Rakhi L, Alfaro JM, Wagner EF, Izquierdo M (2008) Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene 27: 641–652.
63. Xia Y, Yang W, Bu W, Ji H, Zhao X, et al. (2013) Differential Regulation of c-Jun Protein Plays an Instrumental Role in Chemoresistance of Cancer Cells. Journal of Biological Chemistry 288: 19321–19329.